Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...
Reexamination Certificate
2006-03-31
2008-09-23
Ungar, Susan (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds expression product or fragment thereof of...
C424S130100, C424S139100, C424S141100, C424S142100, C530S387100, C530S387700, C530S388100, C435S007100
Reexamination Certificate
active
07427399
ABSTRACT:
Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
REFERENCES:
patent: 5001225 (1991-03-01), Taylor
patent: 6323321 (2001-11-01), Buhring
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 7067130 (2006-06-01), Challita-Eid et al.
patent: 7226594 (2007-06-01), Jakobovits et al.
patent: 2002/0137139 (2002-09-01), Byatt et al.
patent: 2003/0165505 (2003-09-01), Challita-Eid et al.
patent: 2003/0191073 (2003-10-01), Challita-Eid et al.
patent: 2003/0206905 (2003-11-01), Challita-Eid et al.
patent: 2005/0055733 (2005-03-01), Sun et al.
patent: 2005/0265921 (2005-12-01), Challita-Eid et al.
patent: 2005/0265924 (2005-12-01), Challita-Eid et al.
patent: 2006/0002993 (2006-01-01), Challita-Eid et al.
patent: 2006/0275211 (2006-12-01), Challita-Eid et al.
patent: 2007/0004913 (2007-01-01), Challita-Eid et al.
patent: WO-99/60164 (1999-11-01), None
patent: WO-00/21990 (2000-04-01), None
patent: WO-01/57272 (2001-08-01), None
patent: WO-01/57273 (2001-08-01), None
patent: WO-01/57274 (2001-08-01), None
patent: WO-01/57275 (2001-08-01), None
patent: WO-01/57276 (2001-08-01), None
patent: WO-01/57277 (2001-08-01), None
patent: WO-01/57278 (2001-08-01), None
patent: WO-01/60860 (2001-08-01), None
patent: WO-01/75067 (2001-10-01), None
patent: WO-01/86003 (2001-11-01), None
patent: WO-02/79411 (2002-10-01), None
patent: WO-03/004514 (2003-01-01), None
patent: WO-03/016475 (2003-02-01), None
patent: WO-03/040340 (2003-05-01), None
Buhring et al., Blood 94(7):2343-2356 (1999).
Buhring et al., Blood 97(10):3303-3305 (2001).
Burgess et al., Journal of Cell Biology 111:2129-2138 (1990).
Colbern et al., J. Inorg. Biochem. (1999) 77:117-120.
Coleman, Research in Immunology 145:33-36 (1994).
Deissler et al., Journal of Biological Chemistry (1995) 270(17):9849-9855.
Houghton and Scheinberg, Seminars in Oncology (1986) 13:165-179.
International Search Report for PCT/US02/36002, mailed on Jan. 5, 2005, 5 pages.
Jin-Hua et al., Genomics 45(2):412-415 (1997).
Lazar et al., Molecular and Cellular Biology 8(3):1247-1252 (1988).
Lederman et al., Molecular Immunology 28:1171-1181 (1991).
Li et al., Proc Natl Acad Sci USA 77:3211-3214 (1980).
Paul (Ed.), Fundamental Immunology, 3rd ed., p. 242 (1993).
Reiger et al., Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlag, Berlin (1976).
Schwartz et al., Proc Natl Acad Sci USA 84:6408-6411 (1987).
Andoh et al., “Genomic structure and promoter analysis of the ecto-phosphodiesterase I gene (PDNP3) expressed in glial cells,” Biochimica et Biophysica Acta (1999) 1446(3):213-224.
Bollen et al., “Nucleotide pyrophosphatases/phosphodiesterases on the move,” Critical Reviews in Biochemistry and Molecular Biology (2000) 35(6):393-432.
Maurice et al., “Characterization of rat hepatocyte plasma membrane domains by monoclonal antibodies,” European Journal of Cell Biology (1985) 39(1):122-129.
Maurice et al., “Biosynthesis and intracellular transport of a bile canalicular plasma membrane protein: studies in vivo and in the perfused rat liver,” Hepatology (1994) 19(3):648-655.
Scott et al., “Biochemical and molecular identification of distinct forms of alkaline phosphodiesterase I expressed on the apical and basolateral plasma membrane surfaces of rat hepatocytes,” Hepatology (1997) 25(4):995-1002.
Supplementary Partial European Search Report for EP 02 79 7088.8, mailed on Oct. 25, 2006, 7 pages.
Dennis, Nature (2006) 442:739-741.
Srivastava, Nature Immunology (2000) 1(5):363-366.
Jain, Scientific American (1994) 271:58-65.
Dillman, Annals of Internal Medicine (1989) 111:592-603.
Weiner, Seminars in Oncology (1999 26(Suppl. 12):41-50.
NCBI Accession No. NP—004439, Version: NP—004439.1, GI:4758298, PRI date: Oct. 14, 1999, pp. 1-4.
Verma et al., Nature (1997) 389:239-242.
Amalfitano et al., Current Gene Therapy (2002) 2:111-133.
Pandha et al., Current Opinion in Investigational Drugs (2000) 1:122-134.
Houdebine, Journal of Biotechnology (1994) 34:269-287.
Restriction Requirement for U.S. Appl. No. 10/005,480, mailed on May 24, 2004.
Response to Restriction Requirement and Amendment Under 37 CFR § 1.111 for U.S. Appl. No. 10/005,480, filed on Jun. 18, 2004.
Non-Final Office Action for U.S. Appl. No. 10/005,480, mailed on Aug. 17, 2004.
Restriction Requirement for U.S. Appl. No. 10/062,109, mailed on Jul. 9, 2004.
Response to Restriction Requirement for U.S.Appl. No. 10/062,109, filed on Jul. 15, 2004.
Non-Final Office Action for U.S. Appl. No. 10/062,109, mailed on Aug. 25, 2004.
Amendment in Response to Non-Final Office Action for U.S. Appl. No. 10/062,109, filed on Sep. 17, 2004.
Final Office Action for U.S. Appl. No. 10/062,109, mailed on Nov. 12, 2004.
Amendment After Final Action (37 CFR § 1.116) for U.S. Appl. No. 10/062,109, filed on Dec. 1, 2004.
Notice of Allowance for U.S. Appl. No. 10/062,109, mailed on May 4, 2005.
Non-Final Office Action for U.S. Appl. No. 10/860,769, mailed on Dec. 5, 2006.
Amemdment in Response to Non-Final Office Action for U.S. Appl. No. 10/860,869, filed on Mar. 5, 2007.
Non-Final Office Action for U.S. Appl. No. 10/859,643, mailed on Nov. 13, 2006.
Amendment in Response to Non-Final Office Action for U.S. Appl. No. 10/859,643, filed on Mar. 5, 2007.
Non-Final Office Action for U.S. Appl. No. 11/097,912, mailed on Nov. 6, 2006.
Non-Final Office Action for U.S. Appl. No. 11/097,864, mailed on Oct. 19, 2006.
Restriction Requirement for U.S. Appl. No. 10/291,241, mailed on Sep. 21, 2005.
Response to Restriction Requirement, filed on Nov. 18, 2005.
Non-Final Office Action for U.S. Appl. No. 10/291,241, mailed on Dec. 29, 2005.
Amendment in Response to Non-Final Office Action for U.S. Appl. No. 10/291,241, filed on Jan. 10, 2006.
Final Office Action for U.S. Appl. No. 10/291,241, mailed on Apr. 5, 2006.
Amendment After Final Action (37 CFF § 1.116) for U.S. Appl. No. 10/291,241, filed on Apr. 19, 2006.
Supplemental Amendment After Final Action (37 CFF § 1.116) for U.S. Appl. No. 10/291,241, filed on Jun. 1, 2006.
Non-Final Office Action for U.S. Appl. No. 10/291,241, mailed on Jun. 28, 2006.
Amendment in Response to Non-Final Office Action for U.S. Appl. No. 10/291,241, filed on Jul. 13, 2006.
Notice of Allowance for U.S. Appl. No. 10/291,241, mailed on Dec. 12, 2006.
Supplementary European Search Report for EP 02 79 7088, mailed on Feb. 5, 2007, 8 pages.
Database EMBL [Online] Accession No. AK024899 (Sep. 29, 2000).
Database Geneseq [Online] Accession No. ADE56103 (Jan. 29, 2005).
Jiang et al., J. Biol. Chem. (2005) 280(6):4656-4662.
Lewin, ed., Genes VI, Chapter 29, pp. 847-848 (1997).
Stancoviski et al., PMAS USA (1991) 88:8691-8695.
Non-Final Office Action from U.S. Appl. No. 10/062,109, mailed Aug. 25, 2004.
Amendment in Response to Non-Final Office Action from U.S. Appl. No. 10/062,109, mailed Sep. 17, 2004.
Final Office Action from U.S. 10/062,109, mailed Nov. 12, 2004.
Amendment after Final Office Action from U.S. Appl. No. 10/062,109, mailed Dec. 1, 2004.
Request for Continued Examination from U.S. Appl. No. 10/062,109, filed via facsimile on Mar. 2, 2005.
Notice of Allowance and Fee(s) Due from U.S. Appl. No. 10/062,109, mailed May 4, 2005.
Non-Final Office Action from U.S. 10/860,769, mailed Dec. 5, 2006.
Amendment in Response to Non-Final Office Action from U.S. Appl. No. 10/860,769, mailed Mar. 5, 2007.
Notice of Allowance and Fee(s) Due from U.S. Appl. No. 10/860,769, mailed Jun. 1, 2007.
Non-Final Office Action from U.S. Appl. No. 10/
Challita-Eid Pia M.
Gudas Jean
Jakobovits Aya
Jia Xiao-chi
Kanner Steven B.
Agensys, Inc.
Goddard Laura B
Ungar Susan
LandOfFree
Antibodies and related molecules that bind to 161P2F10B... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies and related molecules that bind to 161P2F10B..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies and related molecules that bind to 161P2F10B... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3973614